These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 19298914

  • 21. Safety and efficacy of indigenously developed and manufactured bivalirudin in moderate/high-risk Indian patients undergoing percutaneous coronary intervention: the Bivaflo Registry.
    Seth A, Sinha N, Parikh K, Patel T, Hiremath MS, Mehta AB, Chandra P, Pinto B, Sethi KK, Sengottuvelu S.
    Indian Heart J; 2008; 60(4):333-41. PubMed ID: 19242012
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry.
    Bangalore S, Cohen DJ, Kleiman NS, Regev-Beinart T, Rao SV, Pencina MJ, Mauri L, EVENT Registry Investigators, Boston, MA.
    Circ Cardiovasc Interv; 2011 Oct 01; 4(5):463-73. PubMed ID: 21972401
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Outcomes of patients with prior coronary artery bypass grafting and acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
    Nikolsky E, McLaurin BT, Cox DA, Manoukian SV, Xu K, Mehran R, Stone GW.
    JACC Cardiovasc Interv; 2012 Sep 01; 5(9):919-26. PubMed ID: 22995879
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale.
    Stone GW, Bertrand M, Colombo A, Dangas G, Farkouh ME, Feit F, Lansky AJ, Lincoff AM, Mehran R, Moses JW, Ohman M, White HD.
    Am Heart J; 2004 Nov 01; 148(5):764-75. PubMed ID: 15523305
    [Abstract] [Full Text] [Related]

  • 32. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes.
    Schwenkglenks M, Brazier JE, Szucs TD, Fox KA.
    Value Health; 2011 Jan 01; 14(1):24-33. PubMed ID: 21211483
    [Abstract] [Full Text] [Related]

  • 33. A risk score to predict bleeding in patients with acute coronary syndromes.
    Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, Parise H, Fahy M, Manoukian SV, Feit F, Ohman ME, Witzenbichler B, Guagliumi G, Lansky AJ, Stone GW.
    J Am Coll Cardiol; 2010 Jun 08; 55(23):2556-66. PubMed ID: 20513595
    [Abstract] [Full Text] [Related]

  • 34. Prognostic value of angiographic lesion complexity in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the acute catheterization and urgent intervention triage strategy trial).
    Goto K, Lansky AJ, Ng VG, Pietras C, Nargileci E, Mehran R, Parise H, Feit F, Ohman EM, White HD, Bertrand ME, Desmet W, Hamon M, Stone GW.
    Am J Cardiol; 2014 Dec 01; 114(11):1638-45. PubMed ID: 25312637
    [Abstract] [Full Text] [Related]

  • 35. Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention.
    Verheugt FW, Steinhubl SR, Hamon M, Darius H, Steg PG, Valgimigli M, Marso SP, Rao SV, Gershlick AH, Lincoff AM, Mehran R, Stone GW.
    JACC Cardiovasc Interv; 2011 Feb 01; 4(2):191-7. PubMed ID: 21349458
    [Abstract] [Full Text] [Related]

  • 36. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
    Rajagopal V, Lincoff AM, Cohen DJ, Gurm HS, Hu T, Desmet WJ, Kleiman NS, Bittl JA, Feit F, Topol EJ.
    Am Heart J; 2006 Jul 01; 152(1):149-54. PubMed ID: 16824845
    [Abstract] [Full Text] [Related]

  • 37. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial.
    Gibson CM, Morrow DA, Murphy SA, Palabrica TM, Jennings LK, Stone PH, Lui HH, Bulle T, Lakkis N, Kovach R, Cohen DJ, Fish P, McCabe CH, Braunwald E, TIMI Study Group.
    J Am Coll Cardiol; 2006 Jun 20; 47(12):2364-73. PubMed ID: 16781360
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Prognostic significance of elevated baseline troponin in patients with acute coronary syndromes and chronic kidney disease treated with different antithrombotic regimens: a substudy from the ACUITY trial.
    Acharji S, Baber U, Mehran R, Fahy M, Kirtane AJ, Lansky AJ, Stone GW.
    Circ Cardiovasc Interv; 2012 Apr 20; 5(2):157-65. PubMed ID: 22354934
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.